CHROMBIO. 6181

# Enzymic preparation of dioxygen-18 labelled leukotriene $E_4$ and its use in quantitative gas chromatography-mass spectrometry

Dimitrios Tsikas\*, Joachim Fauler and Jürgen C. Frölich

Department of Clinical Pharmacology, Hannover Medical School, Konstanty-Gutschow-Strasse 8, W-3000 Hannover 61 (Germany)

(First received August 7th, 1991; revised manuscript received October 14th, 1991)

## ABSTRACT

A simple and rapid method is described for the preparation of a stable isotope oxygen-18 labelled leukotriene  $E_4$  (LTE<sub>4</sub>). Oxygen-18 labelling of LTE<sub>4</sub> methyl ester in oxygen-18 water catalysed by a pig liver esterase resulted in the incorporation of two oxygen-18 atoms in the carboxylic group of LTE<sub>4</sub> to the extent of 89.8% ([<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub>) and one oxygen-18 atom to the extent of 9.4% ([<sup>16</sup>O<sup>18</sup>O]LTE<sub>4</sub>), with only 0.7% remaining unchanged ([<sup>16</sup>O<sub>2</sub>]LTE<sub>4</sub>). [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> was found not to back-exchange following incubation in acidified urine (pH 4.0) at 4°C for up to 20 h. [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> was demonstrated to be a useful internal standard in a method for the quantitative determination of LTE<sub>4</sub> in human urine involving high-performance liquid chromatography and gas chromatography with negative-ion chemical ionization tandem mass spectrometry: the concentration of LTE<sub>4</sub> in a 24-h urine sample of a healthy subject was determined to be 68.1 pg/ml.

## INTRODUCTION

Leukotriene  $E_4$  (LTE<sub>4</sub>) is the major urinary metabolite in humans of  $LTC_4$  [1–3], which is one of the most potent lipid mediators of anaphylaxis and inflammation [4]. Quantitative determination of urinary LTE<sub>4</sub> was found to be useful to study the rate of synthesis of cysteinyl leukotrienes in human health and diseases [5-7]. Commonly, quantitation of LTE4 is performed by radioimmunoassay [8,9] or enzyme-linked immunoassay [10] after its separation by reversedphase high-performance liquid chromatography (RP-HPLC). Gas chromatography-mass spectrometry (GC-MS), which is widely used for the quantitation of eicosanoids in biological fluids, has recently been reported to be suitable for the analysis of LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> [11]. This method is based on the catalytic conversion of these compounds into 5-hydroxyeicosanoic acid (5-HEA), which can be sensitively analysed by GC-MS. Accurate and selective quantitation of LTE<sub>4</sub> in urine by this method requires, however, a stable isotope-labelled LTE<sub>4</sub> analogue as internal standard, and separation of LTE<sub>4</sub> by RP-HPLC from other cysteinyl leukotrienes and 5hydroxyeicosatetraenoic acid (5-HETE) because these are also converted to 5-HEA. The use of deuterated LTE<sub>4</sub> analogues seems to be unsuitable because, during catalytic hydrogenation, exchange of deuterium with hydrogen occurs in these compounds [11]. On the other hand, <sup>18</sup>Olabelled 5-HETE as internal standard for LTE<sub>4</sub> [11] is suitable only for semi-quantitative determination, because its HPLC behaviour is different from that of LTE<sub>4</sub>.

This paper describes the enzymic preparation of  $[{}^{18}O_2]LTE_4$  from LTE<sub>4</sub> methyl ester, using a commercially available pig liver esterase according to standard methods for the labelling of eicosanoids [12–14]. The usefulness of this stable isotope-labelled LTE<sub>4</sub> analogue in the quantitative GC-MS determination of LTE<sub>4</sub> in human urine is also demonstrated.

# EXPERIMENTAL

## Chemicals and reagents

LTE<sub>4</sub> free acid, LTE<sub>4</sub> methyl ester and N,Ndiisopropylethylamine were purchased from Sigma (Munich, Germany). [14,15-<sup>3</sup>H(N)]LTE<sub>4</sub> was obtained from DuPont (Dreieich, Germany). Pig liver esterase (PLE, 130 units/mg) was from Boehringer Mannheim (Mannheim, Germany). H<sub>2</sub><sup>18</sup>O (97.8 atom% oxygen-18) was obtained from MSD Isotopes Merck Frosst Canada (Montreal, Canada).  $Li^{18}OH$  (0.36 M) was prepared by dissolving the appropiate amount of lithium in H<sub>2</sub><sup>18</sup>O. The catalyst used for reduction of LTE<sub>4</sub> was 5% (w/w) Rh on Al<sub>2</sub>O<sub>3</sub> and purchased from Fluka (Neu Ulm, Germany). Pentafluorobenzyl (PFB) bromide was obtained from Aldrich (Steinheim, Germany) N,O-bis(trimethylsilyl)trifluoroacetamide and (BSTFA) was from Pierce (Rockford, IL, USA). Acetonitrile and methanol of gradient grade were purchased from Merck (Darmstadt, Germany).

# Solid-phase extraction and reversed-phase HPLC

Solid-phase extraction on 300-mg Sep-Pak  $C_{18}$  cartridges from Waters and RP-HPLC of enzyme incubation mixtures and urine samples were performed as described previously [7]. Gradient elution at a flow-rate of 1.0 ml/min was used. The effluent was monitored at 280 nm. Quantitation of enzymically synthesized [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> was performed by RP-HPLC using appropriate amounts of synthetic LTE<sub>4</sub> and a molar absorptivity (*a*) of 40 000. Identical retention times for synthetic LTE<sub>4</sub> and [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> were found (45.55 min).

# Enzymic preparation of $[^{18}O_2]LTE_4$

LTE<sub>4</sub> methyl ester (25  $\mu$ g in 65% aqueous methanolic potassium phosphate buffer, pH 7.0) and PLE (195 units in ammonium sulphate suspension) were dried under vacuum. The PLE residue was disolved in 90  $\mu$ l of H<sub>2</sub><sup>18</sup>O, and this suspension was used for dissolving the residue of the LTE<sub>4</sub> methyl ester solution. The pH was adjusted to 7.5 by treating the resulting suspension with 5  $\mu$ l of 0.36 *M* Li<sup>18</sup>OH. The mixture was incubated at 37°C for 16 h. The reaction was stopped by addition of 500  $\mu$ l of ice-cold ethanol, and the mixture was allowed to stand at -20°C for 30 min. Thereafter, the mixture was diluted with 1 ml of water and centrifuged (2000 g, 5 min). Aliquots of 100  $\mu$ l were injected into the **RP-HPLC** system, and the peaks with the retention time of synthetic LTE<sub>4</sub> were collected. LTE<sub>4</sub> was recovered by solid-phase extraction and stored in methanol-water (1:1, v/v) at -80°C.

## Catalytic reduction and derivatization

LTE<sub>4</sub> and <sup>18</sup>O-labelled LTE<sub>4</sub> were converted into the corresponding 5-HEAs by catalytic reduction and desulphurization, using 5% (w/w)  $Rh/Al_2O_3$  and hydrogen gas by the modified method of Balazy and Murphy [11]. Briefly, 5 mg of the catalyst were suspended in a methanolic solution of  $LTE_4$ , the suspension was gently shaken and allowed to stand for 5 min on ice, and hydrogen gas was bubbled through the suspension for 20 min at 0°C. Thereafter the sample was centrifuged (2000 g, 5 min), methanol was taken up, the catalyst washed with 1 ml of methanol and the suspension centrifuged again. The combined methanol supernatants were evaporated under a stream of nitrogen, the residue was reconstituted in 1 ml of water and extracted twice with 1 ml of ethyl acetate, and the solvent was dried over sodium sulphate and then removed under nitrogen. 5-HEAs obtained from this process were converted by standard derivatization procedures into their PFB ester trimethylsilyl (TMS) ether derivatives using PFB bromide followed by BSTFA.

## Gas chromatography-mass spectrometry

GC-MS and GC-MS-MS were performed on a Finnigan 9611 gas chromatograph equipped with a fused-silica capillary column OV-1 (25 m  $\times$  0.25 mm I.D., 0.25  $\mu$ m film thickness) from Macherey-Nagel (Düren, Germany) connected to a Finnigan MAT TSQ 45 mass spectrometer (San Jose, CA, USA). The injector was kept at 280°C, and the column held at 100°C for 2 min, then programmed to 320°C at 25°C/min. The column led directly into the ion source which was kept at 120°C. Helium was used as a carrier gas at a pressure of 55 kPa. A constant temperature of 240°C was kept at the interface. Methane was used as reagent gas for negative-ion chemical ionization (NICI) at a pressure of 65 Pa. The ionization energy was 90 eV for NICI and 70 eV for electron impact (EI) at an electron current of 300  $\mu$ A. In GC-MS-MS experiments, argon was used for collision-activated dissociation (CAD) at a collision cell pressure at 3 mTorr. The collision energy was set at 20 eV. The electron multiplier voltage was 2000 V.

## RESULTS AND DISCUSSION

The EI mass spectrum of the PFB-TMS derivative of <sup>18</sup>O-labelled LTE<sub>4</sub> is shown in Fig. 1. The ion at m/z 313 results from fragmentation between carbon atoms 4 and 5 ( $C_{16}H_{32}$  -OTMS)<sup>+</sup>, and was also observed from unlabelled LTE<sub>4</sub>. In contrast, the ion at m/z 373 was observed only from <sup>18</sup>O-labelled LTE<sub>4</sub> and results from fragmentation between carbon atoms 5 and  $6 (C_5H_7 - TMSO - {}^{18}O_2PFB)^+$ , and is increased by four atom mass units (a.m.u.) with respect to the corresponding ion (m/z 369) of unlabelled LTE<sub>4</sub>. The EI mass spectrum of enzymically <sup>18</sup>O-labelled LTE<sub>4</sub> clearly indicates that this compound is [1,1-18O<sub>2</sub>]5-hydroxyeicosanoic acid, which is formed from enzymically produced [1,1-<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> by catalytic reduction and desulphurization.

In Fig. 2 the NICI mass spectrum of enzymically <sup>18</sup>O-labelled LTE<sub>4</sub> is shown. The most intense ions are m/z 403 (M - PFB)<sup>-</sup> and m/z 313  $(M - PFB - TMSOH)^{-}$ . They are increased by four a.m.u. with respect to unlabelled LTE<sub>4</sub> (m/z)399 and 309, respectively). These findings indicate that two <sup>18</sup>O atoms were incorporated in the molecule of LTE<sub>4</sub>. Furthermore, the NICI mass spectrum of <sup>18</sup>O-labelled LTE<sub>4</sub> shows a significantly less intensive signal at m/z 401 (incorporation of one <sup>18</sup>O atom) and no signal at m/z 399 (no incorporation of <sup>18</sup>O atoms). The extent of the incorporation of <sup>18</sup>O atoms into LTE<sub>4</sub> was determined by NICI selected-ion monitoring (SIM) on m/z 403, m/z 401 and m/z 399. Fig. 3 shows a partial GC-MS chromatogram from the NICI-SIM analysis at these ions of enzymically prepared [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> after RP-HPLC separation. Integration of the area of the peaks with scan number 2792 gave 89.8% [18O2]LTE4, 9.4% <sup>16</sup>O<sup>18</sup>O|LTE<sub>4</sub> and 0.7% unlabelled LTE<sub>4</sub>. The total yield of [18O2]LTE4 was determined to be 16% (4  $\mu$ g) by HPLC and UV detection (280 nm,  $a = 40\ 000$ ).

The applicability of  $[^{18}O_2]LTE_4$  as an internal standard was checked by catalytic hydrogenation of various amounts of LTE<sub>4</sub> (zero to 10 ng) each




Fig. 1. EI mass spectrum of the PFB ester TMS ether derivative of  $[1,1^{-18}O_2]$ 5-HEA obtained from enzymically prepared  $[^{18}O_2]LTE_4$  after HPLC analysis, catalytic reduction and desulphurization.




Fig. 2. NICl mass spectrum from the PFB ester TMS ether derivative of enzymically prepared  $[{}^{18}O_2]LTE_4$  after HPLC analysis, catalytic reduction and desulphurization.

spiked with 0.55 ng of  $[^{18}O_2]LTE_4$ . Linear regression of the ratio m/z 399 to 403 (y) on the amount of LTE<sub>4</sub> (x) gave a straight line, with the regression equation y = 0.084 + 1.678x (r > 0.985).

The usefulness of  $[{}^{18}O_2]LTE_4$  as an internal standard in the quantitative determination of LTE<sub>4</sub> in human urine by GC-MS-MS was investigated by analysis of 20-ml urine samples spiked with  $[{}^{18}O_2]LTE_4$  and  $[{}^{3}H]LTE_4$  as de-

scribed in Experimental and in ref. 7. Fig. 4 shows a partial NICI GC-MS-MS chromatogram from a human urine sample spiked with 3 ng of  $[^{18}O_2]LTE_4$  obtained by SIM at m/z 253. This ion was also observed from CAD of the parent ions (M – PFB)<sup>-</sup> on m/z 399 (LTE<sub>4</sub>) and m/z403 ( $[^{18}O_2]LTE_4$ ) (Fig. 5). As CAD of the parent ions (M – PFB)<sup>-</sup> of the deuterated internal standards [20,20,20-<sup>2</sup>H<sub>3</sub>]LTE<sub>4</sub> and [14,15,17,17,18,18-<sup>2</sup>H<sub>6</sub>]LTE<sub>4</sub> leads to the forma-




Fig. 3. Partial GC-MS chromatogram obtained from enzymically prepared  $[^{18}O_2]LTE_4$  by SIM on m/z 403 ( $[^{18}O_2]LTE_4$ ), m/z 401 ( $[^{16}O^{18}O]LTE_4$ ) and m/z 399 ( $[^{16}O_2]LTE_4$ ).




Fig. 4. Partial GC-MS-MS chromatogram from the analysis of a human urine sample (20 ml) spiked with 3 ng of  $[{}^{18}O_2]LTE_4$ . SIM on m/z 253, the same daughter ion of endogenous LTE<sub>4</sub> and  $[{}^{18}O_2]LTE_4$  (see also Fig. 5). The concentration of endogenous LTE<sub>4</sub> in this urine sample was 68.1 pg/ml.

tion of daughter ions with m/z 256 and m/z 259 respectively, due to the number of deuterium atoms, these daughter ions of LTE<sub>4</sub>s probably result from loss of a moiety containing both oxygen atoms of the carboxylic group [15]. The 5-HEA derivatives of endogenous LTE<sub>4</sub> as well as [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> emerged from the column at the same time. The concentration of endogenous LTE<sub>4</sub> in this urine sample was determined to be 68.1 pg/ml.

Back-exchange of <sup>18</sup>O with <sup>16</sup>O in <sup>18</sup>O-labelled eicosanoids is a common phenomenon, which mainly depends on esterase activities in biological materials and the ability of eicosanoids to form lactones [14]. Under the conditions used in our method for solid-phase extraction of LTE4 from urine and HPLC separation [7], and catalytic reduction and desulphurization as described, no back-exchange was observed following separate incubation of 3 ng of  $[^{18}O_2]LTE_4$  in 20 ml of acidified urine (pH 4.0) at 4°C for 30 min and 20 h. The ratios of the peak areas of  $[{}^{16}O_2]LTE_4$  to  $[{}^{18}O_2]LTE_4$  were determined to be 0.454 and 0.481, respectively. This difference lies within the variance of the reproducibility of the method. Also, [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> may be useful for GC-MS quantitation of LTE<sub>4</sub> in other biological

materials when esterase-catalysed back-exchange is avoided by enzyme denaturation, as has been previously reported for other <sup>18</sup>O-labelled eicosanoids [12–14].

The use of pig liver esterases and  $H_2^{18}O$  to introduce <sup>18</sup>O atoms into the carboylic group of LTE<sub>4</sub> methyl esters is an elegant method to prepare rapidly and easily [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> under mild conditions with sufficient yield. [<sup>18</sup>O<sub>2</sub>]LTE<sub>4</sub> is stable in urine for several hours and during catalytic hydrogenation/desulphurization, has the same retention time on RP-HPLC as endogenous LTE<sub>4</sub>, and is therefore a useful internal standard in the quantitative determination of endogenous LTE<sub>4</sub> in human urine by GC–MS. Other <sup>18</sup>Olabelled cysteinyl leukotrienes could be prepared by this method and used as internal standards in GC–MS quantitation of their endogenous analogues.

## ACKNOWLEDGEMENTS

This work was supported by grants from the Deutsche Forschungsgemeinschaft Fr 366/5-2 and Bundesministerium für Forschung und Technologie 01VM90020.




Fig. 5. Daughter mass spectra of unlabelled LTE<sub>4</sub> (a) and  $[{}^{18}O_2]LTE_4$  (b) as their 5-HEAs PFB-TMS derivatives obtained by CAD of the corresponding parent ions (M - PFB)<sup>-</sup> on m/z 399 and m/z 403, respectively. The collision cell pressure was 3 mTorr and the collision energy 20 eV.

#### REFERENCES

- M. Huber, S. Kästner, J. Schölmerich, W. Gerok and D. Keppler, *Eur. J. Clin. Invest.*, 19 (1989) 53.
- N. H. Maltby, G. W. Taylor, J. M. Ritter, K. Moore, R. W. Fuller and C. T. Dollery, J. Allergy Clin. Immunol., 85 (1990)
  3.
- 3 L. Örning, L. Kaijser and S. Hammarström, Biochem. Biophys. Res. Commun., 130 (1985) 214.
- 4 B. Samuelsson, Science (Washington, D.C.), 220 (1983) 568.
- 5 M. Huber, J. Müller, I. Leier, G. Jedlitschky, H. A., Ball, K. P. Moore, G. W. Taylor, R. Williams and D. Keppler, *Eur. J. Biochem.*, 195 (1990) 309.
- 6 A. P. Sampson, D. A. Spencer, C. P. Green, P. J. Piper and J. F. Price, Br. J. Clin. Pharmacol., 30 (1990) 861.
- 7 J. Fauler, D. Tsikas, M. Holch, A. Seekamp, M. L. Nehrlich, J. Sturm and J. C. Frölich, *Clin. Sci.*, 80 (1991) 497.

- 8 L. Levine, R. A. Morgan, R. A. Lewis, K. F. Austen, D. A. Clark, A. Marfat and E. J. Corey, *Proc. Natl. Acad. Sci. U.S.A.*, 78 (1981) 7692.
- 9 E. C. Hayes, D. L. Lombardo, Y. Girard, A. Maycock, J. Rokach, A. S. Rosenthal, R. N. Young and H. J. Zweerink, *J. Immunol.*, 131 (1983) 429.
- 10 P. Pradelles, J. Grassi and J. Maclont, *Anal. Chem.*, 57 (1985) 1170.
- 11 M. Balazy and R. C. Murphy, Anal. Chem., 58 (1986) 1098.
- 12 W. C. Picket and R. C. Murphy, *Anal. Biochem.*, 111 (1981) 115.
- 13 J. Y. Westcott, K. L. Clay and R. C. Murphy, Biomed. Mass Spectrom., 12 (1985) 714.
- 14 H.-J. Leis, W. Welz and E. Malle, J. Chromatogr., 526 (1990) 169.
- 15 D. Tsikas, J. Fauler and J. C. Frölich, in preparation.